# MapLight Therapeutics, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/MapLight Therapeutics, Inc.). ## Overview MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing small-molecule therapies for central nervous system disorders. Its pipeline is built around muscarinic receptor programs, including ML-007C-MA for schizophrenia and Alzheimer's disease psychosis and ML-004 for autism spectrum disorders. ## Products & services • ML-007C-MA for schizophrenia and Alzheimer's disease psychosis • ML-004 for autism spectrum disorders • Muscarinic M1/M4 agonist discovery platform • Preclinical and clinical-stage CNS drug development • Intellectual property licensing and collaboration-based development - **Clinical-stage product candidates** (0%) — Drug candidates under preclinical and clinical development for CNS indications. - **Discovery platform** (0%) — Internal platform used to identify circuit-specific pathways and new indications. - **Licensed intellectual property** (0%) — In-licensed and acquired technology rights supporting the pipeline. - **Collaborative development** (0%) — Strategic collaborations and licensing arrangements that may support development. - ML-007C-MA for schizophrenia and Alzheimer's disease psychosis - ML-004 for autism spectrum disorders - Muscarinic M1/M4 agonist discovery platform - Preclinical and clinical-stage CNS drug development - Intellectual property licensing and collaboration-based development ## Customers MapLight does not yet sell commercial products, so its direct customers are not patients or hospitals today. Its economic stakeholders are future pharmaceutical buyers, payors, and potential licensing or collaboration partners that would support development and eventual commercialization of its CNS programs. - **Future patients in CNS indications** (primary) — Patients with schizophrenia, Alzheimer's disease psychosis, and autism spectrum disorders who would use approved therapies if development succeeds. - **Pharmaceutical collaboration partners** (secondary) — Potential partners that may fund, license, or co-develop MapLight's programs to reduce development risk and extend reach. - **Healthcare payors and reimbursement systems** (secondary) — Public and private payors that would need to cover any approved therapy, affecting adoption and pricing power. - **Clinicians and treatment centers** (secondary) — Psychiatrists, neurologists, and specialty care providers who would prescribe and administer approved CNS treatments. - Future patients with schizophrenia, ADP, and autism spectrum disorders - Healthcare providers who would prescribe approved therapies if launched - Payers and reimbursement bodies that would determine access and coverage - Pharma partners that may license, co-develop, or commercialize assets - Regulators that determine whether product candidates can reach market ## Geography MapLight is a U.S.-based company and currently expects commercialization efforts, if any, to begin in the United States. Its reported exposure is therefore concentrated in U.S. clinical development, regulatory review, and future market access, with additional dependence on third-party CROs, CMOs, and collaborators that may operate globally. - Headquartered in the United States - Current development and planned initial commercialization focus on the U.S. - Relies on third-party CROs and CMOs that may be located outside the U.S. - No country-level revenue disclosed because the company has no product sales - Geographic risk is mainly regulatory, supply-chain, and macroeconomic exposure ## Strategy MapLight's strategy is to advance its muscarinic receptor pipeline through clinical development while expanding the number of indications it can address. The company is also focused on preserving capital, securing additional funding or collaborations, and building intellectual property protection until it can reach commercialization, if ever. - **Advance lead programs through clinical and preclinical milestones** (short-term) — Clinical progress is the main value driver for a company with no commercial revenue. - **Broaden the platform into additional indications** (medium-term) — More indications can improve the probability of success and expand the addressable market. - **Secure external capital and strategic collaborations** (short-term) — The company will need substantial additional funding before any product revenue is possible. - **Build intellectual property and development capability** (medium-term) — Patent protection and development execution are essential to future commercialization value. - Advance ML-007C-MA and ML-004 through clinical development - Expand the platform into additional circuit-specific indications - Use collaborations and licensing to offset capital needs - Protect and enforce intellectual property around core programs - Preserve cash to fund operations through 2027 ## Risks MapLight faces the classic risks of a clinical-stage biotech: no product revenue, heavy cash burn, and uncertainty around clinical success, regulatory approval, and reimbursement. Its muscarinic CNS programs also face competitive pressure, IP risk, and dependence on third-party manufacturers and research vendors, which can disrupt timelines and increase costs. - **Clinical development failure** [critical] — The company is still testing product candidates and may not demonstrate safety or efficacy. - **Financing and dilution risk** [high] — The company expects substantial additional capital needs before any product sales. - **Competitive displacement** [high] — Other biotech and pharma companies may reach the market faster or with better therapies. - **Intellectual property protection** [high] — Weak or challenged patents could allow competitors to copy or block commercialization. - **Third-party manufacturing and CRO dependence** [medium] — Clinical supply and trial execution rely on external vendors and contractors. - No commercial revenue yet, so value depends on clinical success - Substantial losses and future funding needs may dilute shareholders - Clinical trials may fail or take longer than expected - Competitors may develop safer or more effective CNS therapies - IP disputes or weak patent coverage could erode exclusivity - Third-party CRO/CMO disruptions could delay clinical supply ## Accounting The company currently has no product revenue, so reported results are driven mainly by R&D spending, public-company overhead, and non-cash items such as stock compensation and equity-method losses. Investors should watch estimates around clinical and preclinical costs, fair value of investments, and milestone-based obligations tied to prior asset purchases and licenses. - **Research and development expense estimation** — Affects operating loss and comparability across quarters - **Equity method investment accounting** — Can create non-cash volatility in other income/expense - **Stock-based compensation** — Inflates operating expenses without immediate cash outflow - **Milestone and license obligations** — Can affect cash needs and dilution - **Going-concern and runway assumptions** — Important for liquidity assessment and financing risk - No product revenue yet, so losses are driven by R&D and G&A - Stock-based compensation affects reported operating expenses - Equity-method accounting for Stellaromics can create non-cash losses - Milestone obligations from asset purchases may create future expense - Cash runway estimates depend on management assumptions and timing --- *Last updated: 2026-04-28T20:26:15.999530+00:00*